Public institutions
Public research and care organisations contribute to the ecosystem.
THE ADVANCED THERAPY LANDSCAPE
Advanced therapies.
A shared ecosystem.
Understand the technologies. Explore the places.
Read the evidence.
A LANDSCAPE OF CONNECTED CAPABILITIES
Different perspectives. One shared landscape.
OUR TOOLS
Five ways to explore the same evidence.
Complementary views of one dated snapshot.
Keep the source and exact record in view.
THREE TECHNOLOGY FAMILIES
Different approaches.
A common purpose.
Click a family to see its centres and records.
A product can sit in more than one family; the EU legal class is a separate question.
FROM RESEARCH TO PATIENT ACCESS
A shared journey.
A simplified overview. Each product follows its own development
and authorisation pathway.
- 01
Research
Discovery and preclinical development
- 02
Manufacturing & quality
Process development, production and quality control
- 03
Clinical development
Clinical trials and evidence generation
- 04
Patient access
Authorisation, clinical use and commercialisation where applicable
This overview does not establish the readiness, authorisation or availability of a particular centre.
A SHARED ECOSYSTEM
Different organisations. Complementary roles.
Private organisations
Companies contribute technologies, development and production expertise.
Academic institutions
Universities, research institutes and teaching hospitals support research and translation.
Roles can overlap. Public/private ownership is not inferred from the record's academic, hospital or industrial profile.
Understanding the limits of the evidence
Read the source, date and exact subject of each claim. An accreditation, a declared activity and a trial listing describe different evidence. Missing information does not establish an absence of capability. Shared criteria do not establish a partnership.
Sources and methodology →PLANNED WORKFLOW · NOT ACTIVE
What you can do now
Explore the value chain →GEOGRAPHIC ATLAS
Who does what, and where?
Evidence perspectiveAccreditation, declarations and regulatory scope are different evidence.
Records include transplantation context. Inclusion does not establish EU ATMP status, current capacity or treatment availability.
→→→
Documented relationships only
◎
Your question comes first.
Select a technology, a medical application or a place to reveal the landscape.
◎
No mapped evidence in this selection.
Read the symbols +
Cell Gene Tissue
Fixed sectors show presence, not proportion.
Ex vivoIn vivoBothNot reported
Split blue / red = both. C / G / T = therapy families. Institution symbols: cross = hospital, cap = academic, factory = industrial, M = multiple profiles, ? = unspecified. Numbers = grouped records. Open a group to spread up to eight exact records; dashed leader lines show their original positions, not partnerships. A group halo is shown only if every record has the same explicitly reported approach.
Lines: dated, documented organisation relationships. No inferred collaborations.
Country outlines are schematic and can misplace borders and coastlines. Read each record’s locality and coordinate scope; the map is not a site-location plan.
HOW IT WORKS
Explore with context.
Keep the evidence in view.
The Atlas is designed to help you navigate a landscape. It does not rank treatment quality or establish that a therapy is available to a patient.
Different axes, different questions.
Families organise technologies. Organisation profiles describe the institution. Activities describe its role. A hospital may also be academic; a technology may appear in more than one family.
Preclinical studies belong within R&D. A capability and a regulatory authorisation are separate claims.
Filter the claims, not just the names.
Selecting a source changes which evidence supports your results. “All sources” is a combined view, not a verification label.
Different descriptions remain visible with their dates. Corroboration depends on the independence and scope of the sources, not simply on their number.
A disease needs an explicit link.
A general platform does not establish expertise in every associated indication. A trial site does not automatically manufacture the investigational product.
Trial conditions are shown as the registry states them. A centre is never presented as expert in an indication because it works with a platform technology. Planned and historical activities keep their own labels.
Coverage is not completeness.
A map point is a documented location. Source records, organisations, sites and units are different entities. Unknown locations should remain in the list without invented coordinates.
The “Visible map area” list follows the map when you pan or zoom. Choose “All matching records” or “Without a map position” to see the other records; your main filters stay unchanged.
Comparable is not a partner.
Choose one starting centre. Comparable centres appear immediately, nearest first: same activity and same classification at the level you choose (family, technology class or specific technology), or the same trial, project or named product. Neither proves a partnership.
“Why each centre matches” shows the evidence on both sides. The map shows comparable centres with coordinates; the network groups them by organisation name. Distances: 100 km, 1,000 km, 5,000 km or worldwide. A missing result does not establish a worldwide absence.
Real records. Explicit limits.
This release contains … records and … evidence statements from … source labels, including … curated core records. The tools open on the main activities (R&D, Manufacturing, Trials): … records and … evidence statements. These are not verified worldwide totals or certified unique centres.
Centres and source records. A source record is how one database lists an organisation: a ClinicalTrials.gov or CTIS trial-site listing, an NIH or CORDIS grantee, an accreditation, a manufacturing authorisation. Records with the same name in the same city are shown together as one centre, with counts in each source’s own unit (trials, funded projects, products, accreditations). They are not merged: each source record can still be opened on its own, and a shared name does not prove a single site.
Data as of 8 October 2026. Six documented organisation relationships keep their original references and dates. The coverage report lists the corrections, external checks and remaining gaps. Classification corrections made by rule are shown on each record with the original value.
Supplement of 13 October 2026 (R&D and manufacturing only): national authority lists (PEI, ANSM, MHRA, AEMPS, FAMHP, PMDA), EMA product information, industry lists (FIRM, ARM, company websites) and research funders (ANR, UKRI, AMED, CIRM, NSF, SBIR/STTR). Each record keeps its source and the page it was read on; borderline products (acellular scaffolds, devices, processed allografts) are not included.
Technology families are not legal classes.
Under Regulation (EC) 1394/2007, an ATMP is a gene therapy medicinal product (GTMP), a somatic cell therapy medicinal product (sCTMP) or a tissue-engineered product (TEP); a combined ATMP also contains a medical device. When a product fits several classes, precedence applies: a product that could be a TEP or an sCTMP is a TEP, and one that also qualifies as a GTMP is a GTMP. Genetically modified cells such as CAR-T cells are therefore GTMPs, although the Atlas lists them under Cell › Immune cells.
Cells or tissues that are not substantially manipulated and are used for the same essential function (for example most haematopoietic stem-cell transplants and cord blood) are not ATMPs; the Atlas shows them as “Transplantation & SoHO context (not ATMP)”. The hospital exemption (Article 28) covers custom-made, non-routine ATMPs prepared under a hospital’s responsibility. The Atlas families Cell, Gene and Tissue describe technologies; they do not decide a product’s legal class.
Section 351 and Section 361 products.
In the United States, cell and gene therapies regulated as biologics under Section 351 of the Public Health Service Act need an IND for clinical trials and a Biologics License Application (BLA) before marketing; CAR-T and gene therapies fall here. Human cells, tissues and cellular or tissue-based products (HCT/Ps) that meet all criteria of 21 CFR 1271.10 — minimal manipulation, homologous use, no combination with another article, and limits on systemic effect — are regulated under Section 361 only, without premarket approval.
“More than minimal manipulation” in US rules is close to, but not the same as, “substantial manipulation” in EU law. Records from US and EU sources keep their own terms. This summary is indicative and is not legal advice.
READ THE FRAMEWORK · EDITORIAL UPDATE 30 SEPTEMBER 2026
Separate the science, the legal route and the evidence.
This guide adds context. It does not assign a regulatory status to any record or change the frozen dataset.
Regulation (EC) No 1394/2007
This is the specific EU framework for advanced therapy medicinal products. Navigation families can overlap; the legal classification applies to the product and its intended use.
Read the regulation ↗A defined national route
Hospital exemption concerns custom-made ATMPs prepared on a non-routine basis for an individual prescription, used in a hospital in the same Member State under a medical practitioner’s responsibility. National authorisation and quality, traceability and pharmacovigilance requirements apply. Being a hospital does not establish eligibility.
Article 28 and national implementation ↗Adoption is not application
The Council adopted the pharma package on 28 September 2026. Its announcement states that European Parliament adoption and Official Journal publication are still needed. Do not treat the reform as already applicable to a record.
Council announcement · 28 September 2026 ↗SoHO and medicinal products
Regulation (EU) 2024/1938 covers quality and safety of substances of human origin. Most provisions apply from 7 August 2027. Check the boundary between donation and starting-material activities and the medicinal-product framework; a SoHO status is not an ATMP manufacturing authorisation.
Scope and application dates ↗Regenerative medical products
Japan uses its own regulatory categories, including a conditional and time-limited approval pathway for regenerative medical products. Retain the jurisdiction, product, approval type and date; do not translate the category automatically into an EU authorisation.
PMDA framework and resources ↗CAR-T is not synonymous with ex vivo
A human report of in vivo BCMA CAR-T therapy was published in The Lancet in 2025. Maturity depends on the specific product and delivery method; a platform name alone does not establish an approach, approval or local capability.
Primary article · Lancet 2025 ↗PM359 (prime editing of autologous haematopoietic stem cells for chronic granulomatous disease): published online on 7 December 2025; issue of 26 March 2026.
Primary article · NEJM ↗WORKING WITH THE TOOLS
Start with a question.
Where is the evidence?
Use Geographic atlas to explore locations. A gold halo marks your selected record. Some points locate a city, not a building. Records without coordinates remain in the list.
How does a technology span activities?
Use Orbitals: choose a family sphere, open a technology branch, then read the records beside it. The rings represent R&D, Manufacturing and Trials. A record can be on more than one ring, so counts overlap.
What can I compare?
Use Connections to inspect a shared reference or similar recorded activity. Each match keeps its own identity and sources. Use Compare for a shortlist of up to five records; the tools do not score quality or current availability.
What is behind a number?
Use Evidence matrix to cross activities, technologies, countries and document types. Read the counting unit above the table, then select a number to inspect its sources. Darker green means a larger count, not better evidence.
Use the coloured buttons on a record to open that same record in another available tool. Activity, therapy, location and source filters remain shared between pages. Entering from a record preserves the current filters; use Reset all to clear them globally. Connections searches across countries; its optional keyword limit concerns the starting record. Review “Your choices” after changing tools.
“All activities” includes related care, collection, company and product records. They are off in the initial main-activity view. All source dates and original fields remain accessible. Counts describe this collection, not all centres worldwide.
Read before you decide.
Check the exact organisation or unit, the recorded activity, its source and its date. A record does not confirm current capacity, treatment access or a partnership.
Explore the records →